Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P.R. China.
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P.R. China; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou 510060, P.R. China.
Cell Rep Med. 2023 Oct 17;4(10):101222. doi: 10.1016/j.xcrm.2023.101222. Epub 2023 Oct 3.
Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical features are comprehensively investigated. Somatic genetic events are largely inconsistent between paired tumors. Compared with solitary CRC, SCRCs have higher prevalence of tumor mutation burden high (TMB-H; 33.3%) and microsatellite-instability high (MSI-H; 29.4%) and different mutation frequencies in oncogenic signaling pathways. Moreover, neutrally evolving SCRC tumors are associated with higher intratumoral heterogeneity and better prognosis. These findings unveil special molecular features, carcinogenesis, and prognosis of sporadic SCRC. Strategies for targeted therapy and immunotherapy should be optimized accordingly.
散发性同步结直肠癌(SCRC)是指在无遗传倾向的个体中同时检测到多个原发性结直肠肿瘤,这在多发性结直肠癌中占大多数,但对其基因组景观和进化动态缺乏深入了解,从而无法优化其治疗方法。在这项研究中,对 51 例 SCRC 患者的 103 个原发肿瘤样本进行了全外显子组测序。全面研究了种系和体细胞突变以及进化和临床特征。配对肿瘤之间的体细胞遗传事件在很大程度上不一致。与单发结直肠癌相比,SCRCs 具有更高的肿瘤突变负担高(TMB-H;33.3%)和微卫星不稳定高(MSI-H;29.4%)以及致癌信号通路中不同的突变频率。此外,中性进化的 SCRC 肿瘤与更高的肿瘤内异质性和更好的预后相关。这些发现揭示了散发性 SCRC 的特殊分子特征、致癌发生和预后。应相应优化针对这些特征的靶向治疗和免疫治疗策略。